Data / Form D filings / Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, Inc.: Form D filings
Adaptive Phage Therapeutics, Inc., a biotechnology company in Gaithersburg, MD, filed 8 Form D notices with the SEC between 2017 and 2023. The latest, on June 9, 2023, reports $12 million sold of a $30 million offering to 4 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 708 Quince Orchard Road, Gaithersburg, MD, 20878
- Phone
- (844) 972-0500
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1701259
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | New notice | $30,000,000 | $11,999,999 | $18,000,001 | 4 | May 25, 2023 | sec.gov |
| May 20, 2021 | New notice | $53,262,037 | $23,262,000 | $30,000,037 | 59 | May 7, 2021 | sec.gov |
| Aug 27, 2020 | Amendment | $3,650,000 | $0 | $3,650,000 | 0 | Yet to occur | sec.gov |
| Aug 24, 2020 | New notice | $7,000,000 | $3,350,000 | $3,650,000 | 18 | Jun 5, 2020 | sec.gov |
| Jun 22, 2020 | New notice | $7,000,000 | $2,825,000 | $4,175,000 | 12 | Jun 5, 2020 | sec.gov |
| Nov 27, 2019 | Amendment | $7,000,000 | $6,994,388 | $5,612 | 40 | Jan 24, 2018 | sec.gov |
| Jun 5, 2018 | New notice | $5,000,000 | $2,350,000 | $2,650,000 | 8 | Jan 24, 2018 | sec.gov |
| Apr 14, 2017 | New notice | $3,000,000 | $765,000 | $2,235,000 | 10 | Feb 2, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan L. Leff | Director | |
| Jana L. Jensen | Director | |
| Carl R. Merril | Director | |
| Ian L. Hardy | Director | |
| Michael L. Orndorff | Executive Officer | |
| Gregory L. Merril | Executive Officer, Director, Promoter | |
| Jesse L. Goodman | Director | |
| Raymond L. Martz | Director | |
| Martin L. Heidecker | Director | |
| Evan L. Loh | Director | |
| Subhendu L. Basu | Executive Officer |
Other biotechnology companies in Maryland that filed recently
- Accufy Diagnostics, Inc. $2 million · Oct 28, 2026
- OS Therapies Inc $7.2 million · Oct 23, 2026
- Kaigene, Inc. $55 million · Oct 14, 2026
- Templar Nova, Inc. $7 million · Oct 7, 2026
- Monocacy Therapeutics Inc. $25,000 · Oct 7, 2026
- Seraxis Holdings, Inc. $10 million · Sep 24, 2026
Every Form D from the week of Jun 5, 2023 · All recent filings in Maryland · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Adaptive Phage Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.